Literature DB >> 2171423

Suppression of herpes simplex virus type 1 reactivation from latency by (+-)-9-([(Z)-2-(hydroxymethyl)cyclohexyl]methyl) guanine (L-653,180) in vitro.

Y A Nsiah1, R L Tolman, J D Karkas, F Rapp.   

Abstract

Latent herpes simplex virus type 1 (HSV-1) infection was induced in human embryonic lung cells in vitro by using a combination of viral replication inhibitors and elevated temperature. Under reactivating conditions (superinfection by human cytomegalovirus or temperature manipulation), a nonantiviral thymidine kinase inhibitor (L-653,180) was found to suppress or delay reactivation of HSV-1 from latently infected human embryonic lung cells. L-653,180 alone or in combination with interferon was ineffective as a primary or acute viral replication inhibitor and was unable to induce latent HSV-1 infection in cell culture. These data suggest that initial or acute virus replication and replication resulting from reactivation from latency are separate events.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171423      PMCID: PMC171871          DOI: 10.1128/AAC.34.8.1551

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Acute infection of differentiated neuroblastoma cells by latency-positive and latency-negative herpes simplex virus ts mutants.

Authors:  J C Gerdes; H S Marsden; M L Cook; J G Stevens
Journal:  Virology       Date:  1979-04-30       Impact factor: 3.616

2.  Latent infections in spinal ganglia with thymidine kinase-deficient herpes simplex virus.

Authors:  T P Leist; R M Sandri-Goldin; J G Stevens
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

3.  Herpes simplex virus latency in cultured human cells following treatment with cytosine arabinoside.

Authors:  F J O'Neill; R J Goldberg; F Rapp
Journal:  J Gen Virol       Date:  1972-02       Impact factor: 3.891

4.  Activation by thymidine kinase and potent antiherpetic activity of 2'-nor-2'-deoxyguanosine (2'NDG).

Authors:  W T Ashton; J D Karkas; A K Field; R L Tolman
Journal:  Biochem Biophys Res Commun       Date:  1982-10-29       Impact factor: 3.575

5.  Reactivation of herpes simplex virus type 2 from a quiescent state by human cytomegalovirus.

Authors:  A M Colberg-Poley; H C Isom; F Rapp
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

6.  Persistence of herpes simplex virus genes in cells of neuronal origin.

Authors:  M Levine; A L Goldin; J C Glorioso
Journal:  J Virol       Date:  1980-07       Impact factor: 5.103

7.  Prolongation of herpes simplex virus latency in cultured human cells by temperature elevation.

Authors:  F J O'Neill
Journal:  J Virol       Date:  1977-10       Impact factor: 5.103

Review 8.  Mechanism of action and selectivity of acyclovir.

Authors:  G B Elion
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

9.  High efficiency latency and activation of herpes simplex virus in human cells.

Authors:  B L Wigdahl; A C Scheck; E De Clercq; F Rapp
Journal:  Science       Date:  1982-09-17       Impact factor: 47.728

10.  Repression and activation of the genome of herpes simplex viruses in human cells.

Authors:  B L Wigdahl; H C Isom; F Rapp
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

View more
  3 in total

1.  Herpes simplex virus thymidine kinase and specific stages of latency in murine trigeminal ganglia.

Authors:  J G Jacobson; K L Ruffner; M Kosz-Vnenchak; C B Hwang; K K Wobbe; D M Knipe; D M Coen
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

2.  Lack of stereospecificity of suid pseudorabies virus thymidine kinase.

Authors:  G Maga; A Verri; L Bonizzi; W Ponti; G Poli; A Garbesi; D Niccolai; S Spadari; F Focher
Journal:  Biochem J       Date:  1993-09-01       Impact factor: 3.857

3.  Assessment of a selective inhibitor of herpes simplex virus thymidine kinase (L-653,180) as therapy for experimental recurrent genital herpes.

Authors:  N Bourne; F J Bravo; W T Ashton; L C Meurer; R L Tolman; J D Karkas; L R Stanberry
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.